REDWOOD CITY, California, March 25 /PRNewswire/ --
Ingenuity Systems, the leading provider of information solutions for life science researchers, today announced it has achieved key milestones in the ongoing Cooperative Research and Development Agreement (CRADA) with the Food and Drug Administration. Significant progress has been made in several areas including the curation of new biomarker and toxicology content and the expansion of existing ontological classifications. These developments will advance the FDA towards its goal of rapidly identifying potential genomic 'fingerprints' that could be used to quickly and easily compare genomic data from submissions of drugs in the same class.
Under the terms of the CRADA, Ingenuity Systems and the FDA will expand Ingenuity's content and software solutions to facilitate the research and regulatory review of biomarker, pharmacogenomic, and toxicogenomic data. The collaboration directly relates to the FDA's need to develop better tools for the review of genomic data.
"We are making progress towards the goals outlined in the CRADA," commented Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics. "We are looking forward to this collaboration over the course of this year so our team can benefit from these tools and information available from them on relationships between drugs and potential mechanism of action and mechanism of toxicity."
"Our collaboration with the FDA was a natural partnership given Ingenuity's close alliance with the industry initiatives and healthcare goals laid out by the Critical Path Initiative," stated Ramon Felciano, Ph.D., CTO and Vice President, Research of Ingenuity Systems. "We are confident that we can leverage Ingenuity's unique capabilities to provide the FDA with a clearer understanding of the biological and chemical relationships embedded in the regulatory data."
About Ingenuity Systems(R)
Ingenuity Systems is a leading provider of information solutions for the exploration, interpretation, and analysis of life science information. All of Ingenuity's products and services have one common goal - to help life science researchers generate maximum value from all types of biological and chemical knowledge. Ingenuity offers a broad and flexible range of solutions that can be tailored to needs of various clients, including academic and therapeutic area researchers, computational biologists and informatics departments, and suppliers in the life sciences industry. All of the products leverage Ingenuity's knowledge base, the largest data base of its kind, which houses the biological and chemical relationships extracted from scientific literature. The information is uniquely structured so scientists can ask complex biological questions to gain rapid insight into their experimental data or create relevant biological models to move forward in their research. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, and academic research institutions worldwide. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, Australia, and Japan. http://www.ingenuity.com.
Web site: http://www.ingenuity.com
Heidi Bullock, Director, Marketing of Ingenuity Systems, +1-650-381-5150
Comments